Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Investing Activities (2020 - 2023)

Journey Medical (DERM) has disclosed Cash from Investing Activities for 4 consecutive years, with -$5.0 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Cash from Investing Activities rose 75.0% year-over-year to -$5.0 million, compared with a TTM value of -$5.0 million through Dec 2023, up 75.0%, and an annual FY2024 reading of -$15.0 million, down 200.0% over the prior year.
  • Cash from Investing Activities was -$5.0 million for Q1 2023 at Journey Medical, up from -$20.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$200000.0 in Q4 2020 and bottomed at -$20.0 million in Q1 2022.
  • Average Cash from Investing Activities over 4 years is -$6.6 million, with a median of -$3.1 million recorded in 2021.
  • The sharpest move saw Cash from Investing Activities tumbled 500.0% in 2021, then surged 75.0% in 2023.
  • Year by year, Cash from Investing Activities stood at -$200000.0 in 2020, then crashed by 500.0% to -$1.2 million in 2021, then crashed by 1566.67% to -$20.0 million in 2022, then soared by 75.0% to -$5.0 million in 2023.
  • Business Quant data shows Cash from Investing Activities for DERM at -$5.0 million in Q1 2023, -$20.0 million in Q1 2022, and -$1.2 million in Q4 2021.